How AMT-143 could reduce the post-surgical need for opioids
In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation.
Watch the AMT-143 animation below:
The short video explains how AMT-143, our first formulation, addresses the critical 72-hour postoperative period when patients report the highest pain levels. When approved, it may help to reduce patients’ risk of opioid dependency while increasing relief.
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.
AmacaThera’s drug development platform is featured in Innovate Toronto, an in-depth look at Toronto’s innovation ecosystem. The online compendium and coffee table book features over 300 start-up success stories, including Kepler, which aims to take the Internet into space, and Altus Assessments, which is using data and tech to bring the human side of healthcare education back into focus. Read more